ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner

Molecular and Cellular Biology

Volumn 18, Issue 9, 1998, Pages 5042-5051

  Olayioye, Monilola A ^a   Graus Porta, Diana ^a   Beerli, Roger R ^a,c   Rohrer, Jack ^a   Gay, Brigitte ^b   Hynes, Nancy E ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; DIMERIZATION; HORMONE RECEPTOR INTERACTION; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0031840484     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.18.9.5042     Document Type: Article

References (53)

1. Bargmann, C. I., M.-C. Hung, and R. A. Weinberg. 1986. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649-657.
2. Baulida, J., M. H. Kraus, M. Alimandi, P. P. Di Fiore, and G. Carpenter. 1996. All ErbB receptors other than the epidermal growth factor are endocytosis impaired. J. Biol. Chem. 271:5251-5257.
3. Beerli, R. R., and N. E. Hynes. 1996. Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J. Biol. Chem. 271:6071-6076.
4. Beerli, R .R., D. Graus-Porta, K. Woods-Cook, X. Chen, Y. Yarden, and N. E. Hynes. 1995. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol. Cell. Biol. 15:6496-6506.
5. Beerli, R. R., W. Wels, and N. E. Hynes. 1994. Autocrine inhibition of the epidermal growth factor receptor by intracrine expression of a single-chain antibody. Biochem. Biophys. Res. Commun. 204:666-672.
6. Beerli, R. R., W. Wels, and N. E. Hynes. 1994. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J. Biol. Chem. 269: 23931-23936.
7. Braunwalder, A. F., L. Weennogle, B. Gay, K. E. Lipson, and M. Sills. 1996. Application of scintillating microtiter plates to measure phosphopeptide interactions with the Grb2 SH2 binding domain. J. Biomol. Screening 1:23-26.
8. Chen, X., G. Levkowitz, E. Tzahar, D. Karunagaran, S. Lavi, N. Ben-Baruch, O. Leitner, B. J. Ratzkin, S. S. Bacus, and Y. Yarden. 1996. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J. Biol. Chem. 271:7620-7629.
9. Cohen, B. D., J. M. Green, L. Foy, and H. P. Fell. 1996. HER4-mediated biological and biochemical properties in NIH 3T3 cells. J. Biol. Chem. 271:4813-4818.
10. Cohen, B. D., P. A. Kiener, J. M. Green, L. Foy, P. Fell, and K. Zhang. 1996. The relationship between human epidermal growth-like factor receptor and cellular transformation in NIH3T3 cells. J. Biol. Chem. 271:30897-30903.
11. Cohen, G. B., R. Ren, and D. Baltimore. 1995. Modular binding domains in signal transduction proteins. Cell 80:237-248.
12. Daly, J. M., C. B. Jannot, R. R. Beerli, D. Graus-Porta, F. G. Maurer, and N. E. Hynes. 1997. Neu differentiation factor induces ErbB-2 down-regulation and apoptosis of ErbB-2 overexpressing breast tumor cells. Cancer Res. 57:3804-3811.
13. Dankort, D. L., Z. Wang, V. Blackmore, M. F. Moran, and W. J. Muller. 1997. Distinct tyrosine autophosphorylation sites negatively and positively modulate Neu-mediated transformation. Mol. Cell. Biol. 17:5410-5425.
14. Davis, R. J., and M. P. Czech. 1984. Tumor-promoting phorbol diesters mediate phosphorylation of the epidermal growth factor receptor. J. Biol. Chem. 259:8545-8549.
15. Decker, S. 1984. Effects of epidermal growth factor and 12-O-tetradecanoylphorbol-13-acetate on metabolism of the epidermal growth factor receptor in normal human fibroblasts. Mol. Cell. Biol. 4:1718-1724.
16. DiGuglielmo, G. M., P. C. Baass, W.-J. Ou, B. I. Posner, and J. J. M. Bergeron. 1994. Compartmentalization of SHC, GRB2 and mSOS, and hyperphosphorylation of Raf-1 by EGF but not insulin in liver parenchyma. EMBO J. 13:4269-4277.
17. Druker, B. J., H. J. Mamon, and T. M. Roberts. 1989. Oncogenes, growth factors, and signal transduction. N. Engl. J. Med. 321:1283-1391.
18. Emlet, D. R., D. K. Moscatello, L. B. Ludlow, and A. J. Wong. 1997. Subsets of epidermal growth factor receptors during activation and endocytosis. J. Biol. Chem. 272:4079-4086.
19. French, A. R., D. K. Tadaki, S. K. Niyogi, and D. A. Lauffenburger. 1995. Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction. J. Biol. Chem. 270:4334-4340.
20. Fukazawa, T., K. A. Reedquist, T. Trub, S. Soltoff, G. Panchamoorthy, B. Druker, L. Cantley, S. E. Shoelson, and H. Band. 1995. The SH2 domain-binding T cell tyrosyl phosphoprotein p120. Demonstration of its identity with the c-cbl protooncogene product and in vivo complexes with Fyn, Grb2, and phosphotidlyinositol 3′-kinase. J. Biol. Chem. 270:19141-19150.
21. Graus-Porta, D., R. R. Beerli, J. M. Daly, and N. E. Hynes. 1997. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16:1647-1655.
22. Graus-Porta, D., R. R. Beerli, and N. E. Hynes. 1995. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol. 15:1182-1191.
23. Gullick, W. J., D. J. Downward, J. G. Foulkes, and M. D. Waterfield. 1985. Antibodies to the ATP-binding site of the human epidermal growth factor (EGF) receptor as specific inhibitors of EGF-stimulated protein-tyrosine kinase activity. EMBO J. 4:2869-2877.
24. Harwerth, I.-M., W. Wels, B. M. Marte, and N. E. Hynes. 1992. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J. Biol. Chem. 267:15160-15167.
25. Harwerth, I.-M., W. Wels, J. Schlegel, M. Müller, and N. E. Hynes. 1993. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br. J. Cancer 68:1140-1145.
26. Holgado-Madruga, M., D. E. Emlet, D. K. Moscatello, A. K. Godwin, and A. J. Wong. 1996. A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature 379:560-564.
27. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9:1165-1172.
28. Hynes, N. E., H. A. Gerber, S. Saurer, and B. Groner. 1989. Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J. Cell. Biochem. 39:167-173.
29. Hynes, N. E., and D. F. Stern. 1994. The biology of erbB-2/neu/HER2 and its role in cancer. Biochim. Biophys. Acta 1198:165-184.
30. Karunagaran, D., E. Tzahar, R. R. Beerli, X. Chen, D. Graus-Porta, B. J. Ratzkin, R. Seger, N. E. Hynes, and Y. Yarden. 1996. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 15:254-264.
31. Kavanaugh, W. M., and L. T. Williams. 1994. An alternative to SH2 domains for binding tyrosine-phosphorylated proteins. Science 266:1862-1865.
32. Levkowitz, G., L. N. Klapper, E. Tzahar, A. Freywald, M. Sela, and Y. Yarden. 1996. Coupling of the c-Cbl protooncogene to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene 12:1117-1125.
33. c-src with two major signaling pathways in human breast cancer. Proc. Natl. Acad. Sci. USA 91:83-87.
34. Meisner, H., and M. P. Czech. 1995. Coupling of the proto-oncogene product c-Cbl to the epidermal growth factor receptor. J. Biol. Chem. 270:25332-25335.
35. Messerle, K., J. Schlegel, N. E. Hynes, and B. Groner. 1994. NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypecally reverted by a kinase deficient, dominant negative erbB-2 variant. Mol. Cell. Endocrinol. 105:1-10.
36. Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587-3596.
37. Muthuswamy, S. K., and W. J. Muller. 1995. Direct and specific interaction of c-Src with neu is involved in signaling by the epidermal growth factor receptor. Oncogene 11:271-279.
38. Olayioye, M. A. Unpublished data.
39. Pinkas-Kramarski, R., L. Soussan, H. Waterman, G. Levkowitz, I. Alroy, L. Klapper, S. Lavi, R. Seger, B. J. Ratzkin, M. Sela, and Y. Yarden. 1996. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15:2452-2467.
40. S6k. FEBS Lett. 410:78-82.
41. Riese II, D. J., Y. Bermingham, T. M. van Raiij, S. Buckley, G. D. Plowman, and D. F. Stern. 1996. Betacellulin activates the epidermal growth factor receptor and erbB-4 and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-β. Oncogene 12:345-353.
42. Riese, D. J., II, and D. F. Stern. 1998. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20:41-48.
43. Robinson, M. J., and M. H. Cobb. 1997. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9:180-186.
44. Salomon, D. S., R. Brandt, F. Ciardiello, and N. Normanno. 1995. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19:183-232.
45. Shoyab, M. G., G. Plowman, V. L. McDonald, J. G. Bradley, and G. J. Todaro. 1989. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 243:1074-1076.
46. Sorkin, A., and C. M. Waters. 1993. Endocytosis of growth factor receptors. Bioessays 15:375-382.
47. Stover, D. R., M. Becker, J. Liebetanz, and N. B. Lydon. 1995. Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and p85α. J. Biol. Chem. 270:15591-15597.
48. Tzahar, E., H. Waterman, X. Chen, G. Levkowitz, D. Karunagaran, S. Lavi, B. J. Ratzkin, and Y. Yarden. 1996. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 16:5276-5287.
49. Wang, J., K. R. Auger, L. Jarvis, Y. Shi, and T. M. Roberts. 1995. Direct association of Grb2 with the p85 subunit of phosphatidylinositol 3-kinase. J. Biol. Chem. 270:12774-12780.
50. Wang, Z., and M. F. Moran. 1996. Requirement for the adapter protein Grb2 in EGF receptor endocytosis. Science 272:1935-1939.
51. Weiss, F. U., H. Daub, and A. Ullrich. 1997. Novel mechanisms of RTK signal generation. Curr. Opin. Genet. Dev. 7:80-86.
52. Zhang, K., J. Sun, N. Liu, D. Wen, D. Chang, A. Thomason, and S. K. Yoshinage. 1996. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem. 271:3884-3890.
53. Zrihan-Licht, S., J. Lim, I. Keydar, M. X. Sliwkowski, J. E. Groopman, and H. Avraham. 1997. Association of Csk-homologous kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in breast cancer cells. J. Biol. Chem. 272:1856-1863.